LC-MS

Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer

Retrieved on: 
Monday, January 29, 2024
CMC, Mass spectrometry, CSO, Biotechnology, Chromatography, GMP, Peptide, Functional, Spacecraft, LC-MS, Antibody, Protein, Dicarboxylic acid, Doctor of Philosophy, Biopharmaceutical, Proteomics, Genentech, Assay, Growth, Fine chemical

CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).

Key Points: 
  • CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).
  • We are thrilled to announce that Dr. Shiaw-Lin (Billy) Wu has joined Crystal Bio as its new co-founder and Chief Scientific Officer (CSO).
  • With over three decades of experience in analytical and bioanalytical analysis of biologics for CMC development, Dr. Wu is a valuable addition to the Crystal Bio team.
  • We are excited to have him on board and look forward to his contributions in driving innovation and growth at Crystal Bio.

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity

Retrieved on: 
Wednesday, January 10, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CITES, Mass spectrometry, UPLC, Multimedia, QPS, Peptide, DMPK, Drug discovery, LC-MS, Laboratory, Therapy, Doctor of Philosophy, Biomarker, HRMS, Oligonucleotide, SFC, Growth, Fine chemical

QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).

Key Points: 
  • QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
  • View the full release here: https://www.businesswire.com/news/home/20240110198636/en/
    Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • (Photo: Business Wire)
    This expansion includes the impressive growth seen in 2023, when QPS installed seven additional UPLC-(HR)MS/MS tandem instruments - four triple quadrupoles, one QTRAP, and two quadrupole time-of-flight high-resolution mass spectrometers (HRMS).
  • QPS Subject Matter Experts are some of the best in the industry and this new equipment will provide the capacity for them to expand their relationships with our important biotech and pharmaceutical clients,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.

Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device

Retrieved on: 
Wednesday, January 3, 2024
Senate, LC-MS, Cannabis, Collection, Workflow, Smoking, Washington State, Health, MSBS, THC, California State Assembly, Mass, Patent, Vaccine, Biomarker, BCU, OTC, LSA

The MSBS substantially simplifies laboratory analysis methods, reduces sample turnaround times (within a few minutes), and provides a truly novel method for drug screening using breath.

Key Points: 
  • The MSBS substantially simplifies laboratory analysis methods, reduces sample turnaround times (within a few minutes), and provides a truly novel method for drug screening using breath.
  • Cannabix is advancing discussions with industry leading forensic laboratory organizations on how to best integrate its novel MSBS hardware into current forensic testing and analysis methods.
  • The new provisional patent covers various novel aspects for efficient analysis of low volatility analytes from human breath developed by the Company.
  • This equipment significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

Retrieved on: 
Wednesday, December 6, 2023
Shimadzu, Research, Proteomics, Mass spectrometry, Agilent Technologies, LC-MS, Laboratory, SCIEX, Nano, Partnership, Chromatography, 3D printing, Warehouse, Bruker

IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.

Key Points: 
  • IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.
  • This partnership underscores IonOpticks' commitment to broadening the accessibility and application of its top-tier chromatography technologies.
  • Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora Series columns are now seamlessly compatible with Agilent mass spectrometers.
  • This collaboration marks a significant advancement in IonOpticks' drive to empower all researchers with the best chromatography, regardless of the mass spec they are using, with a similar solution for Shimadzu mass specs coming soon.

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

Retrieved on: 
Wednesday, December 6, 2023
Shimadzu, Research, Proteomics, Mass spectrometry, Agilent Technologies, LC-MS, Laboratory, SCIEX, Nano, Partnership, Chromatography, 3D printing, Warehouse, Bruker

IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.

Key Points: 
  • IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.
  • This partnership underscores IonOpticks' commitment to broadening the accessibility and application of its top-tier chromatography technologies.
  • Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora Series columns are now seamlessly compatible with Agilent mass spectrometers.
  • This collaboration marks a significant advancement in IonOpticks' drive to empower all researchers with the best chromatography, regardless of the mass spec they are using, with a similar solution for Shimadzu mass specs coming soon.

Cannabis Testing Market to grow by USD 1.50 billion from 2022-2027 | Increasing global awareness about the benefits of cannabis drives the market growth - Technavio

Retrieved on: 
Wednesday, November 8, 2023
Cannabis, Research, ROW, LC-MS, Information management, Software, Segment, Growth, USD, Drug, Retail, Cannabidiol, Geography

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.
  • Increasing global awareness about the benefits of cannabis drives the growth of the cannabis testing market.
  • Factors like advances in instruments in recent years have increased their adoption in the global cannabis testing market.
  • Growth of the cannabis testing market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of cannabis testing market vendors.

Quantitative Bioanalysis of Antibody-Drug Conjugates by Mass Spectrometry, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 24, 2023
Biomarker, Bioanalysis, LC-MS, ADC, Associate Director of National Intelligence and Chief Information Officer, PK, Antibody, Toxicity, Therapy, Drug development, Fine chemical

TORONTO, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into bioanalytical complexity, strategy and regulatory considerations when developing ADC therapeutics with a focus on developing and validating liquid chromatography-mass spectrometry (LC-MS) pharmacokinetics (PK) assays.

Key Points: 
  • In this free webinar, gain insights into the complexity, comprehensive strategy and regulatory considerations for bioanalysis in support of the development of drug-conjugated antibody (ADC).
  • Attendees will learn bioanalytical strategies for ADC drug development and how to apply the PK assay results to inform on ADC stability and dose selection.
  • Antibody-drug conjugates are a new and fast-growing class of targeted drugs consisting of "antibodies, cytotoxic drugs and linkers".
  • Join experts from Amador Bioscience , Meina Liang, Chief Technology Officer (CTO), President of Bioanalysis & Biomarkers; and Andrea Ngai, Associate Director, Bioanalysis & Biomarkers, for the live webinar on Wednesday, November 8, 2023, at 12pm EST (9am PST).

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits

Retrieved on: 
Thursday, October 19, 2023
Acceleration, Science, FDA, NYSE, Therapy, Extraction (chemistry), LC-MS, Oligonucleotide, ChromeOS, Metabolism, Drug development, Contract research organization, SPE, Workflow, Laboratory, Kits, WAT, MS, Waters Corporation, Fine chemical, Pharmaceutical industry

MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x[i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

Key Points: 
  • MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides.
  • The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline.
  • Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation.
  • Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis.

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits

Retrieved on: 
Thursday, October 19, 2023
Acceleration, Science, FDA, NYSE, Therapy, Extraction (chemistry), LC-MS, Oligonucleotide, ChromeOS, Metabolism, Drug development, Contract research organization, SPE, Workflow, Laboratory, Kits, WAT, MS, Waters Corporation, Fine chemical, Pharmaceutical industry

MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x[i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

Key Points: 
  • MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides.
  • The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline.
  • Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation.
  • Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis.